The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.
Read Article
Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers.
A current review focuses commonly used serologies and autoimmune tests to identify
Read Article
A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates
Read Article
A new user cohort study of 109 504 gout patients, achieving a serum urate level less than 6 mg/dL, was associated with a significantly lower risk of cardiovascular events.
Read Article
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity. Originally developed for B cell malignancies, this innovative immunotherapy
Read Article
A population based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid
With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by a recent Cochrane review.
Do shoes make a difference in osteoarthritis (OA)? Common advice often suggests that stable supportive shoes can improve arthritis symptoms in the knee, but does this apply to hip osteoarthritis?
Read Article
Dry eye rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung Memorial Hospital in Keelung, Taiwan, and colleagues
Read Article
A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course.
Read Article
An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.
While most would advocate for using your best therapy
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.
Read Article
“Orthopedics or rheumatology, who should I see?" A question, often asked with urgency, posed by those who genuinely don’t know who to see for a musculoskeletal (MSK) complaint. Inquiring patients, family, or other physicians may be one forum for such a request. Another occurs in the
Read Article
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians has published a new ethics/position policy paper proclaiming that the term ‘provider’ should not be used to describe physicians, and using the blanket term
Read Article
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
Read Article
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market.
Originally developed by ChemoCentryx, the oral
Read Article
The American College of Rheumatology (ACR) today applauded the recent passage of the Congressional CY 26 funding package that includes several important provisions, including extending Medicare telehealth payment flexibilities, improving transparency in pharmacy benefit management (PBM)
Read Article
A cost-effectiveness analysis compared FDA approved fibromyalgia drugs (pregabalin, duloxetine, milnacipran) with amitriptyline and found duloxetine was the preferred strategy across perspectives.
Read Article
A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX.
Read Article
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
